Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma
NCT ID: NCT04167280
Last Updated: 2020-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
12 participants
INTERVENTIONAL
2019-11-05
2020-03-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness
NCT00605410
Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma
NCT05113615
Reversibility of Methacholine Induced Bronchoconstriction
NCT05977699
A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients
NCT00331292
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
NCT06433921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ipratropium bromide
20mcg bronchodilator inhaler
Ipratropium Metered Dose Inhaler
MDI to deliver 20mcg per puff ipratropium bromide
placebo
matching bronchodilator inhaler
placebo metered dose inhaler
matched MDI to deliver inactive drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ipratropium Metered Dose Inhaler
MDI to deliver 20mcg per puff ipratropium bromide
placebo metered dose inhaler
matched MDI to deliver inactive drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* adequate baseline lung function
* no respiratory infection or exposure to stimuli that may alter response to methacholine within 4 weeks
Exclusion Criteria
* current smoker
* requirement for medications other than salbutamol that will interfere with airway response to methacholine
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Saskatchewan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Don Cockcroft
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Don Cockcroft, MD
Role: PRINCIPAL_INVESTIGATOR
University of Saskatchewan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Bio REB 1522
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.